Comparing outcomes with low dose vs. high dose 177Lu EDTMP in patients with metastatic bone pain: A single-centre blinded RCT.

被引：0

作者：

Pandey, Rakesh Ramprakash ^{[1
]}

Kumar, Rajesh ^{[1
]}

Taywade, Sameer ^{[1
]}

Majeed, Althaf K. ^{[1
]}

机构：

[1] All India Inst Med Sci, Jodhpur, Rajasthan, India

来源：

JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

P1133

引用

页数：2

共 24 条

[1] Efficacy of 177Lu-EDTMP regarding improvement in mobility and bone pain palliation - Comparison of high dose therapy with low dose
Akhtar, Ghazal
Zaknun, John
Saeed, Shabana
Fatima, Shazia
Butt, Sadaf
Mariani, Giuliano
Irfan, Javaid
JOURNAL OF NUCLEAR MEDICINE, 2012, 53
[2] [177Lu]Lu-EDTMP -a bone pain palliating agent: pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients
Saeed, Shabana
Paez, Diana
Lobato, Enrique Estrada
Bolton, Roberto C. Delgado
Jameel, Ghazal
Qureshi, Farida
Pellet, Olivier
Brink, Anita
Soto, Adrian
Grigoryan, Anna
Knoll, Peter
Giammarile, Francesco
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
[3] 177Lu-EDTMP for bone pain palliation in patients with bone metastases: Pharmacokinetics and toxicity evaluation using dose escalation schedule
Saeed, Shabana
Zaknun, John
Jameel, Ghazal
Ahmed, Naseer
Irfan, Javaid
Fatima, Shazia
Qureshy, Ahmad
Afzal, Muhammad Shahzad
Mariani, Giuliano
JOURNAL OF NUCLEAR MEDICINE, 2012, 53
[4] Efficacy and toxicity profile of low dose 177 Lutetium-Ethylenediamine tetra methylene phosphonate (177Lu-EDTMP) for bone pain palliation in patients with skeletal metastases
Halanaik, A. S. A. D.
Pandit, N.
Ponnusamy, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S371 - S372
[5] Comparative therapeutic efficacy and toxicity profile of low dose (35 mCi) versus high dose (70 mCi) 177Lu-EDTMP for bone pain palliation in metastatic prostate and breast cancer: Initial results from a randomized clinical trial
Agarwal, Krishan K.
Bal, Chandrasekhar
Zaknun, John
Sharma, Punit
Naswa, Niraj
Singla, Suhas
Damle, Nishikant
Malhotra, Arun
JOURNAL OF NUCLEAR MEDICINE, 2012, 53
[6] Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience
Satapathy, Swayamjeet
Mittal, Bhagwant Rai
Sood, Ashwani
Verma, Roshan
Panda, Naresh
NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (07) : 629 - 635
[7] [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Hofman, Michael S.
Violet, John
Hicks, Rodney J.
Ferdinandus, Justin
Thang, Sue Ping
Akhurst, Tim
Iravani, Amir
Kong, Grace
Kumar, Aravind Ravi
Murphy, Declan G.
Eu, Peter
Jackson, Price
Scalzo, Mark
Williams, Scott G.
Sandhu, Shahneen
LANCET ONCOLOGY, 2018, 19 (06): : 825 - 833
[8] Re: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study
De Man, Kathia
Ost, Piet
EUROPEAN UROLOGY, 2019, 75 (03) : 536 - 537
[9] A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
Shin, Dongho
Ha, Seunggyun
Hyun, O. Joo
Rhew, Seung Ah
Yoon, Chang Eil
Kwon, Hyeok Jae
Moon, Hyong Woo
Park, Yong Hyun
Park, Sonya Youngju
Park, Chansoo
Chi, Dae Yoon
Yoo, Ie Ryung
Lee, Ji Youl
CANCERS, 2022, 14 (24)
[10] Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Strosberg, Jonathan R.
Wolin, Edward M.
Chasen, Beth A.
Kulke, Matthew H.
Bushnell, David L.
Caplin, Martyn E.
Baum, Richard P.
Hobday, Timothy J.
Hendifar, Andrew Eugene
Ravasi, Laura
Oberg, Kjell E.
Ruszniewski, Philippe B.
Krenning, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 →